NEW YORK, April 21, 2021 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally acknowledged shareholder rights regulation agency, reminds traders that class actions have been commenced on behalf of stockholders of Repro Med Systems, Inc. d/b/a KORU Medical Systems (NASDAQ: KRMD), SOS Limited (NYSE: SOS), Canoo, Inc. (NASDAQ: GOEV), and Kadmon Holdings, Inc. (NASDAQ: KDMN). Stockholders have till the deadlines under to petition the courtroom to function lead plaintiff. Additional details about every case could be discovered at the hyperlink supplied.
Repro Med Systems, Inc. d/b/a KORU Medical Systems (NASDAQ: KRMD)
Class Period: August 4, 2020 to January 25, 2021
Lead Plaintiff Deadline: May 25, 2021
KORU designs, manufactures, and markets proprietary transportable medical units, primarily for the ambulatory infusion market.
On November 3, 2020, after the market closed, KORU introduced its third quarter 2020 monetary outcomes, reporting that internet gross sales declined sequentially to $6.1 million. During the convention name the subsequent day, the Company attributed the decrease gross sales to, amongst different issues, “greater allowances for gross rebates for sure clients” and “cost reductions and distribution charges.”
On this information, the Company’s inventory fell $1.97, or 32%, to shut at $4.16 per share on November 4, 2020.
On January 25, 2021, after the market closed, KORU introduced its preliminary monetary outcomes for fiscal 2020, anticipating income of roughly $24.0 million, a rise of three.4% over the prior yr. The Company attributed the outcomes to, amongst different issues, “[s]decrease development in internet income on account of strengthening our contractual place with giant clients.” In the press launch, KORU additionally introduced that its CEO, Donald Pettigrew, resigned, efficient instantly.
On this information, KORU’s inventory worth fell $0.80 per share, or 15.5%, to shut at $4.33 per share on January 26, 2021.
The criticism, filed on March 26, 2021, alleges that all through the Class Period defendants made materially false and/or deceptive statements, in addition to failed to disclose materials opposed information about the Company’s enterprise, operations, and prospects. Specifically, defendants failed to disclose to traders that: (1) beginning in January 2020, KORU ramped up the use of allowances, together with development rebates, to retain key clients and to incentivize development; (2) as the rebates accrued, the Company’s internet gross sales had been moderately possible to decline; and (3) on account of the foregoing, defendants’ constructive statements about the Company’s enterprise, operations, and prospects had been materially deceptive and/or lacked an affordable foundation.
For extra data on the Repro Med class motion go to: https://bespc.com/circumstances/KRMD
SOS Limited (NYSE: SOS)
Class Period: July 22, 2020 to February 25, 2021
Lead Plaintiff Deadline: June 1, 2021
When the Company went public in April 2017, it was often called “China Rapid Finance Limited” and claimed to give attention to a peer-to-peer, micro-lending enterprise. The Company later modified its title to “SOS Limited” in July 2020 and bought its peer-to-peer, micro-lending enterprise in August 2020, rebranding itself into an emergency providers enterprise. In January 2021, the Company once more shifted its enterprise focus, this time to cryptocurrency mining.
Critical to SOS’s purportedly profitable transition right into a cryptocurrency mining enterprise had been the Company’s claims to have entered into an settlement with HY International Group New York Inc. (“HY”), which calls itself the “world’s largest mining machine matchmaker,” to purchase 15,645 mining rigs—i.e., private computing machines constructed particularly for cryptocurrency mining—for $20 million, and the Company’s plans to buy FXK Technology Corporation (“FXK”), a purported Canadian cryptocurrency know-how agency.
On February 26, 2021, Hindenburg Research (“Hindenburg”) and Culper Research (“Culper”) launched commentary on SOS, claiming that the Company was an intricate “pump and dump” scheme that used faux addresses and doctored images of crypto mining rigs to create an phantasm of success. The analysts famous, for instance, that SOS’s SEC filings listed a lodge room as the Company’s headquarters. The analysts additionally questioned whether or not SOS had really bought mining rigs that it claimed to personal, as the entity from which SOS purportedly purchased the mining rigs appeared to be a faux shell firm. The analysts additional alleged that the images SOS had revealed of their purported “mining rigs” had been phony. Culper famous that pictures of SOS’s “miners” didn’t depict the A10 Pro machines that the Company claimed to personal and as a substitute appeared to present completely different units altogether. Hindenburg, for its half, discovered that the unique photos from SOS’s web site really belonged to one other firm.
On this information, SOS’s American depositary share worth fell $1.27 per share, or 21.03%, to shut at $4.77 per ADS on February 26, 2021.
The criticism, filed on March 30, 2021, alleges that, all through the Class Period defendants made materially false and deceptive statements concerning the Company’s enterprise, operations, and compliance insurance policies. Specifically, defendants made false and/or deceptive statements and/or failed to disclose that: (i) SOS had misrepresented the true nature, location, and/or existence of at the least one in every of the principal government places of work listed in its SEC filings; (ii) HY and FXK had been both undisclosed associated events and/or entities fabricated by the Company; (iii) the Company had misrepresented the kind and/or existence of the mining rigs that it claimed to have bought; and (iv) because of this, the Company’s public statements had been materially false and deceptive in any respect related occasions.
For extra data on the SOS class motion go to: https://bespc.com/circumstances/SOS
Canoo, Inc. (NASDAQ: GOEV)
Class Period: August 18, 2020 to March 29, 2021
Lead Plaintiff Deadline: June 1, 2021
Canoo was fashioned by a enterprise mixture between Hennessy Capital Acquisition Corp. IV (a particular function acquisition (SPAC) firm) and Canoo Holdings Limited in December 2020. The Company is a cellular know-how firm that develops electrical autos. The criticism, filed on April 2, 2021, alleges that prior to and after the mixture, the Company promoted a enterprise mannequin based mostly on a three-phased method to producing income and development: (i) an engineering providers section, (ii) the gross sales of subscriptions to autos to customers, and (iii) the sale of autos to different companies.
On March 29, 2021, the Company revealed that it was radically altering its enterprise mannequin by deemphasizing its engineering providers enterprise and by now not specializing in its subscription-based enterprise.
In response to this information, shares of Canoo fell $2.50 (or $21.2%) from a March 29, 2021 shut of $11.80 per share to shut at $9.30 per share on March 30, 2021.
The criticism additional alleges that defendants misled traders by misrepresenting and/or failing to disclose that: (i) the Company’s engineering providers section was not a viable enterprise, wouldn’t present significant income in 2021, and wouldn’t cut back operational danger; (ii) that the Company would now not be targeted on its subscription-based enterprise mannequin; and (iii) because of this, the Company’s public statements had been materially false and deceptive in any respect related occasions.
For extra data on the Canoo class motion go to: https://bespc.com/circumstances/GOEV
Kadmon Holdings, Inc. (NASDAQ: KDMN)
Class Period: October 1, 2020 to March 10, 2021
Lead Plaintiff Deadline: June 2, 2021
Kadmon is a biopharmaceutical firm that discovers, develops, and commercializes small molecules and biologics primarily for the therapy of inflammatory and fibrotic ailments. The Company’s lead product candidates embrace, amongst others, belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (“ROCK2”), which is in Phase II scientific improvement for the therapy of persistent graft-versus host illness (“cGVHD”).
On September 30, 2020, post-market, Kadmon introduced the submission of a New Drug Application (“NDA”) for belumosudil for the therapy of cGVHD (the “Belumosudil NDA”) with the U.S. Food and Drug Administration (“FDA”).
On March 10, 2021, Kadmon issued a press launch “announc[ing] that the [FDA] has prolonged the evaluate interval” for the Belumosudil NDA and that, “[i]n a discover acquired from the FDA on March 9, 2021, the Company was knowledgeable that the [PDUFA] aim date for its Priority Review of belumosudil has been prolonged to August 30, 2021.” Kadmon suggested traders that “[t]he FDA prolonged the PDUFA date to permit time to evaluate further data submitted by Kadmon in response to a current FDA data request,” and that “[t]he submission of the further data has been decided by the FDA to represent a serious modification to the NDA, leading to an extension of the PDUFA date by three months.”
On this information, Kadmon’s inventory worth fell $0.52 per share, or 10.57%, to shut at $4.40 per share on March 11, 2021.
The criticism, filed on April 2, 2021, alleges that all through the Class Period defendants made materially false and deceptive statements concerning the Company’s enterprise, operations, and compliance insurance policies. Specifically, defendants made false and/or deceptive statements and/or failed to disclose that: (i) the Belumosudil NDA was incomplete and/or poor; (ii) the further new knowledge that the Company submitted in assist of the Belumosudil NDA in response to an data request from the FDA materially altered the NDA submission; (iii) accordingly, the preliminary Belumosudil NDA submission lacked the diploma of assist that the Company had led traders to consider; (iv) accordingly, the FDA was possible to prolong the PDUFA goal motion date to evaluate the Belumosudil NDA; and (v) because of this, the Company’s public statements had been materially false and deceptive in any respect related occasions.
For extra data on the Kadmon class motion go to: https://bespc.com/circumstances/KDMN
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally acknowledged regulation agency with places of work in New York, California, and South Carolina. The agency represents particular person and institutional traders in business, securities, by-product, and different advanced litigation in state and federal courts throughout the nation. For extra details about the agency, please go to www.bespc.com. Attorney promoting. Prior outcomes don’t assure comparable outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
Marion Passmore, Esq.
(212) 355-4648
[email protected]
www.bespc.com
